Skip to main content

Sequenom Says $3M Charge to Shutter Swedish Space Hurt Net Loss

NEW YORK, July 31 - Sequenom today said that the cost of shuttering a facility in Sweden amidst modest revenue growth caused net loss to nearly double.


The company said total revenue for the period ended was $9.2 million compared with $7.4 million in the same period one year ago. The increase was supported across all three of the company's revenue streams: sales increased by about $700,000 to $5.7 million; services jumped to $3.4 million from $2.3 million; and research receipts swelled to $9.2 million from $7.4 million, all year over year for the second quarter, the company reported.


Total expenses for the second quarter 2002 surged to $24.7 million from $17.6 million one year ago, led by a jump in R&D spending to $8.1 million from $6.8 million in the year-ago period. Sequenom also said it took a $3 million charge in the quarter for closing a facility in Uppsala in September as part of its acquisition of Gemini Genomics that month.


As a result, net loss for the period ballooned to $14.5 million, or $.39 per share, from $8.7 million, or $.36 per share, in the year-ago quarter. Without the $3 million charge Sequenom said the net loss in the current second quarter would be $11.5 million, or $.31 per share.


The company said it had about $114 million in cash, cash equivalents, short-term investments, and restricted cash as of June 30.


Click here for more information.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.